Prospective Randomized Study of Cell Therapy for Metastatic Melanoma Using Short-Term Cultured Tumor Infiltrating Lymphocytes Plus IL-2 Following Either a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Alone or in Conjunction w/1200 TBI

Clinical Trial ID NCT01319565

Rank	Title	Journal	Year	PubWeight™‹?›
1	High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993.	J Clin Oncol	1999	10.86
2	Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens.	J Clin Oncol	2008	10.13
3	Adoptive immunotherapy for cancer: harnessing the T cell response.	Nat Rev Immunol	2012	7.39
4	Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2.	J Natl Cancer Inst	1994	7.20
5	High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update.	Cancer J Sci Am	2000	4.19
6	Trial watch: Chemotherapy with immunogenic cell death inducers.	Oncoimmunology	2012	1.33
7	Akt inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristics.	Cancer Res	2014	1.26
8	Trial Watch: Adoptive cell transfer immunotherapy.	Oncoimmunology	2012	1.18
9	Combinations of radiation therapy and immunotherapy for melanoma: a review of clinical outcomes.	Int J Radiat Oncol Biol Phys	2014	1.03
10	Tumor-infiltrating lymphocytes in melanoma.	Curr Oncol Rep	2012	0.97
11	Durable Complete Response from Metastatic Melanoma after Transfer of Autologous T Cells Recognizing 10 Mutated Tumor Antigens.	Cancer Immunol Res	2016	0.79